We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    UP0110
Previous Study | Return to List | Next Study

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05277571
Recruitment Status : Recruiting
First Posted : March 14, 2022
Last Update Posted : January 23, 2023
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma SRL )

Brief Summary:
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.

Condition or disease Intervention/treatment Phase
Atopic Dermatitis Biological: UCB1381 Drug: Placebo Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 152 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Actual Study Start Date : March 7, 2022
Estimated Primary Completion Date : February 19, 2025
Estimated Study Completion Date : February 19, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema

Arm Intervention/treatment
Experimental: UCB1381 dosing regime 1 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 2 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 3 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 4 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 5 in Part A
Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 6 in Part A
Participants will be randomized to receive a single dose UCB1381 subcutaneously (sc).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 7 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 8 in Part A
Participants will be randomized to receive a single dose UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Experimental: UCB1381 dosing regime 9 in Part B
Participants will be randomized to receive repeated doses UCB1381 intravenously (iv).
Biological: UCB1381
UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

Placebo Comparator: Placebo iv Arm Part A
Participants will be randomized to receive a single dose of placebo iv to maintain the blinding.
Drug: Placebo
Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Placebo Comparator: Placebo sc Arm Part A
Participants will be randomized to receive a single dose of placebo sc to maintain the blinding.
Drug: Placebo
Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Placebo Comparator: Placebo iv Arm Part B
Participants will be randomized to receive repeated doses of placebo iv to maintain the blinding.
Drug: Placebo
Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.




Primary Outcome Measures :
  1. Incidents of treatment-emergent adverse events (TEAEs) from Baseline through the End of Study (EOS) Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.

  2. Incidents of treatment-emergent serious adverse events (TESAEs) from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

    • Results in death
    • Is life-threatening
    • Requires inpatient hospitalisation or prolongation of existing hospitalisation
    • Results in persistent or significant disability/incapacity, or
    • Is a congenital anomaly/birth defect
    • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

  3. Incidents of TEAEs from Baseline through the EOS Visit (Week 22) in Part B [ Time Frame: From Baseline up to Week 22 in Part B ]
    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study medication, whether or not considered related to the study medication. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study medication.

  4. Incidents of TESAEs from Baseline through the EOS Visit (Week 22) in Part B [ Time Frame: From Baseline up to Week 22 in Part B ]

    A serious adverse event (SAE) is any untoward medical occurrence that at any dose:

    • Results in death
    • Is life-threatening
    • Requires inpatient hospitalisation or prolongation of existing hospitalisation
    • Results in persistent or significant disability/incapacity, or
    • Is a congenital anomaly/birth defect
    • Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

  5. ≥75% improvement vs Baseline (Yes/No) in Eczema Area and Severity Index score (EASI75) at Week 12 in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities

    The severity of disease is evaluated by assessing each of 4 clinical signs for each area:

    Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.



Secondary Outcome Measures :
  1. UCB1381 Cmax from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    Cmax: Maximum observed concentration

  2. UCB1381 Tmax from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    Tmax: Time of observed Cmax

  3. UCB1381 AUC(0-t) from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    AUC(0-t): Area under the concentration-time curve from time zero to the time of last detectable concentration.

  4. UCB1381 AUC from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    AUC: Area under the concentration-time curve from time zero to infinity.

  5. UCB1381 F% from Baseline through the EOS Visit (Week 12) in Part A [ Time Frame: From Baseline up to Week 12 in Part A ]
    F%: Bioavailability of subcutaneous administration

  6. Percent change from Baseline in EASI score at Week 12 in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities

    The severity of disease is evaluated by assessing each of 4 clinical signs for each area:

    Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.


  7. ≥50% improvements vs Baseline (Yes/No) in EASI score (EASI50) at Week 12 in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities

    The severity of disease is evaluated by assessing each of 4 clinical signs for each area:

    Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.


  8. ≥90% improvements vs Baseline (Y/N) in EASI score (EASI90) at Week 12 in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]

    The Eczema Area and Severity Index (EASI) is a validated scoring system that grades the physical signs of atopic dermatitis/eczema. A participant's EASI is scored through evaluation of 4 body regions: Head and neck; Trunk; Upper extremities; Lower extremities

    The severity of disease is evaluated by assessing each of 4 clinical signs for each area:

    Erythema; Edema/papulation; Excoriation; Lichenification The severity of each clinical sign is scored as: 0=None, 1=Mild, 2=Moderate, 3=Severe.


  9. Validated Investigator Global Assessment (vIGA) score of 0 or 1 (Y/N) at Week 12 in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]
    vIGA: Validated Investigator Global Assessment score is using descriptors that best describe the overall appearance of the lesions at a given time point. Assessment: vIGA 0=clear, vIGA 1=almost clear, vIGA 2=mild, vIGA 3=moderate, vIGA 4=severe

  10. UCB1381 Cmax at week 12 after the final dose in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]
    Cmax: Maximum observed concentration

  11. UCB1381 Tmax at week 12 after the final dose in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]
    Tmax: Time of observed Cmax

  12. UCB1381 AUCtau at week 12 after the final dose in Part B [ Time Frame: From Baseline up to Week 12 in Part B ]
    AUCtau: Area under the curve for the dosing interval after the final dose.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Part A Healthy study participants

  • Participant must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF)
  • Participant must be overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring
  • Participant has a body mass index (BMI) within the range 18 to 30 kg/m2 (inclusive)
  • Participant can be male or female and must agree to use contraception

Part B Participants with moderate to severe Atopic dermatitis (AtD)

  • Participant must be 18 to 65 years of age inclusive at the time of signing the ICF
  • Participant has moderate or severe AtD that has been present for at least 12 months prior to initiating the study (signing of the ICF) and with:
  • A validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
  • An Eczema Area and Severity Index (EASI) score of ≥14 at Screening and ≥16 at Baseline
  • Pruritis Numerical Rating Scale (NRS) ≥3 at Screening and Baseline

    -≥10 % body surface area (BSA) of AtD involvement at Screening and Baseline

  • Either documented recent history (within 6 months before the Screening Visit) of inadequate response to treatment with topical medications (regular use of topical corticosteroids [TCS] or topical calcineurin inhibitors [TCIs]) or when topical treatments are confirmed to be otherwise medically inadvisable (eg, because of important side effects or safety risks)
  • Participant has a BMI within the range 18 to 35 kg/m2 (inclusive)

Exclusion Criteria:

Part A Healthy study participants

  • Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
  • Participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) or other biologic drugs (including humanized monoclonal antibodies (mAbs)), clinically significant drug allergies, or history of severe adverse reactions after drug administration
  • Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has previously been randomized in this study
  • Participant has participated in another study of an IMP or has received any biologic agent (such as mAbs, including marketed drugs and including biologic agents that target interleukin (IL)-13 or IL-22) within the 30 days prior to Screening or 5 half-lives (whichever is longer), if this information can be validated by the investigator

Part B Participants with moderate to severe AtD

  • Participant has a history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, electrocardiogram (ECG), or vital sign that, in the opinion of the investigator, could significantly alter the absorption, metabolism, or elimination of drugs; constitute a risk when taking the study intervention; or interfere with the interpretation of data
  • Participant has a known hypersensitivity to any components of the IMP or other biologic drugs (including humanized mAbs), clinically significant drug allergies, or history of severe adverse reactions after drug administration
  • Participant has a past history of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
  • Participant has had pharmaceutically active topical therapies for AtD (including mild topical corticosteroids (TCS)) within 2 weeks of the Baseline Visit (corticosteroids, cyclosporin or other calcineurin inhibitors [eg, tacrolimus, pimecrolimus])
  • Participant has received phototherapy or systemic non-biologic therapies for AtD within 4 weeks of the Baseline Visit (including moderate/strong corticosteroids, cyclosporine A or other calcineurin inhibitors, mycophenolate mofetil, azathioprine, methotrexate, or any alternative medicine for AtD, eg, traditional Chinese medicine)
  • Participant has previously used a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)
  • Participant has received any prescription or nonprescription medicines, including over the counter remedies and herbal and dietary supplements (other than vitamins within recommended daily dose limits) within 14 days (or 5 half-lives of the respective drug, whichever is longer) prior to the Baseline Visit, other than contraceptives (oral, implant, or intrauterine devices) or occasional use of analgesics such as paracetamol (acetaminophen, with or without caffeine, with a maximal dose of 4g/day and 10g/14 days) or intranasal corticosteroids for seasonal rhinitis or inhaled bronchodilators and low dose inhaled corticosteroids for mild asthma. In case of uncertainty, the UCB Study Physician should be consulted
  • Participant has previously been randomized in this study
  • Participant has participated in previous studies with a biologic that affects IL-13 or IL-22 pathways, or any JAK inhibitor (including marketed and/or experimental treatments), within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit. Previous use of biologics affecting IL-13 or IL-22 pathways is only accepted if treatment was stopped due to reasons other than inadequate efficacy and safety (eg, administrative reasons, poor convenience, poor access to drug)
  • Participant has participated in another study of an IMP within 30 days or 5 half-lives (whichever is longer) of the Baseline Visit or is currently participating in another study of an IMP

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05277571


Contacts
Layout table for location contacts
Contact: UCB Cares 1-844-599-2273 (USA) ucbcares@ucb.com
Contact: UCB Cares 018445992273 UCBCares@ucb.com

Locations
Layout table for location information
United States, California
Up0110 101 Recruiting
Glendale, California, United States, 91206
Sponsors and Collaborators
UCB Biopharma SRL
Investigators
Layout table for investigator information
Study Director: UCB Cares 001 844 599 2273 (UCB)
Layout table for additonal information
Responsible Party: UCB Biopharma SRL
ClinicalTrials.gov Identifier: NCT05277571    
Other Study ID Numbers: UP0110
First Posted: March 14, 2022    Key Record Dates
Last Update Posted: January 23, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of reidentifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access Criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
URL: http://www.Vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by UCB Pharma ( UCB Biopharma SRL ):
Atopic dermatitis
Phase 1/2A
Healthy study participants
Patients
UCB1381
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Eczema
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases